Dry Skin Cream, Lotion, and Ointment MarketThe global dry skin cream, lotion, and ointment market is on the cusp of substantial expansion, according to recent market analysis. The industry is ...

Sanofi SAN-0.15%decrease; red down pointing triangle forecast stronger earnings growth this year and said it planned to launch a $5.2 billion share buyback. The French pharmaceutical company said ...

Sanofi has tapped Alloy Therapeutics to enable development of a central nervous system drug, agreeing to pay $27.5 million in upfront and near-term fees to access an antisense platform. Alloy is ...

Sanofi’s Q3 revenue grew by 12.3% to €13.438 billion, driven by products like Dupixent and influenza vaccines. Dupixent remains a top growth driver, with potential peak sales exceeding $20 ...

Sanofi's participation at the JP Morgan 43rd Annual Healthcare Conference on 14 January 2025 was marked by a comprehensive overview of the company's position in 2024 and its strategic vision for t ...

Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...

Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid switching between products and could be used to respond to an emerging pandemic ...

LB-102 is a modified version of amisulpride, a dopamine inhibitor that was developed in the 1980s and marketed by Sanofi as a schizophrenia drug—Solian—outside the U.S. High doses of ...

The Brooks Glycerin 22 has been specifically engineered for optimal comfort and durability for a wide range of runners. Whether you're a casual jogger, enjoy a daily walk or are a dedicated ...

Brooks Glycerin 21 Running Shoes are now on sale for $130—a modest but always welcome $30 discount on their normal $160 selling price. The newest iteration in the storied Glycerin series ...